{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T01:35:45Z","timestamp":1789349745537,"version":"build-2803163510"},"reference-count":97,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.hoc.2012.07.009","type":"journal-article","created":{"date-parts":[[2012,8,28]],"date-time":"2012-08-28T14:30:33Z","timestamp":1346164233000},"page":"1101-1116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical Predictors of Outcome in MPN"],"prefix":"10.1016","volume":"26","author":[{"given":"Francesco","family":"Passamonti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Maffioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Merli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ferrario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Caramazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2012.07.009_bib1","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib2","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3324\/haematol.13346","article-title":"Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients","volume":"93","author":"Passamonti","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2012.07.009_bib3","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2012.07.009_bib4","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.hoc.2012.07.009_bib5","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2007-11-121434","article-title":"A\u00a0dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis","volume":"111","author":"Passamonti","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib6","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/cncr.21297","article-title":"Leukemic transformation of polycythemia vera: a single center study of 23 patients","volume":"104","author":"Passamonti","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2012.07.009_bib7","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","article-title":"Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm","volume":"115","author":"Beer","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2012.07.009_bib8","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A\u00a0prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2012.07.009_bib9","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/sj.leu.2404500","article-title":"Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients","volume":"21","author":"Gangat","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2012.07.009_bib10","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2141.2007.06674.x","article-title":"Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation","volume":"138","author":"Gangat","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2012.07.009_bib11","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2012.07.009_bib12","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/ajh.21496","article-title":"Blast phase of essential thrombocythemia: A single center study","volume":"84","author":"Passamonti","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2012.07.009_bib13","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bjorkholm","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2012.07.009_bib14","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2012.07.009_bib15","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2008.72","article-title":"Life expectancy and prognostic factors in the classic BCR\/ABL-negative myeloproliferative disorders","volume":"22","author":"Cervantes","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2012.07.009_bib16","first-page":"307","article-title":"Polycythemia rubra vera","volume":"22","author":"Bilgrami","year":"1995","journal-title":"Semin Oncol"},{"key":"10.1016\/j.hoc.2012.07.009_bib17","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1182\/blood-2010-08-270033","article-title":"How I treat essential thrombocythemia","volume":"117","author":"Beer","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib18","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2012.07.009_bib19","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.clml.2011.01.002","article-title":"Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis","volume":"11","author":"Passamonti","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.hoc.2012.07.009_bib20","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3324\/haematol.12970","article-title":"Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain","volume":"93","author":"Ziakas","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2012.07.009_bib21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.leukres.2008.06.006","article-title":"Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia","volume":"33","author":"Dahabreh","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.hoc.2012.07.009_bib22","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib23","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib24","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","article-title":"Characteristics and clinical correlates of MPL 515W>L\/K mutation in essential thrombocythemia","volume":"112","author":"Vannucchi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib26","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2012.07.009_bib27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1600-0609.2009.01246.x","article-title":"Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance","volume":"83","author":"Gangat","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hoc.2012.07.009_bib28","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/leu.2008.218","article-title":"Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs)","volume":"22","author":"Reilly","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2012.07.009_bib29","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1182\/blood-2008-04-153783","article-title":"Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia","volume":"112","author":"Carobbio","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib30","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2007.15.3569","article-title":"Leukocytosis and risk stratification assessment in essential thrombocythemia","volume":"26","author":"Carobbio","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2012.07.009_bib31","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1538-7836.2009.03531.x","article-title":"Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia","volume":"7","author":"Passamonti","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2012.07.009_bib32","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00277-010-1154-3","article-title":"Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study","volume":"90","author":"Palandri","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.hoc.2012.07.009_bib33","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00277-009-0706-x","article-title":"Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms","volume":"88","author":"Caramazza","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.hoc.2012.07.009_bib34","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1002\/cncr.24664","article-title":"Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera","volume":"115","author":"Gangat","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2012.07.009_bib35","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols","volume":"23","author":"Berk","year":"1986","journal-title":"Semin Hematol"},{"key":"10.1016\/j.hoc.2012.07.009_bib36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2007-05-091850","article-title":"Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes","volume":"111","author":"Wilkins","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib37","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","article-title":"Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification","volume":"117","author":"Thiele","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2012.07.009_bib38","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment","volume":"120","author":"Passamonti","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib39","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A\u00a0gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2012.07.009_bib40","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2012.07.009_bib41","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib42","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMc1006966","article-title":"LNK mutations in JAK2 mutation-negative erythrocytosis","volume":"363","author":"Lasho","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2012.07.009_bib43","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1365-2141.2009.07860.x","article-title":"A\u00a0new polycythaemia vera-associated SOCS3 SH2 mutant (SOCS3F136L) cannot regulate erythropoietin responses","volume":"147","author":"Suessmuth","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2012.07.009_bib44","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.hoc.2012.07.009_bib45","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2012.07.009_bib46","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3324\/haematol.2010.034488","article-title":"The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms","volume":"96","author":"Olcaydu","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2012.07.009_bib47","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2012.07.009_bib48","first-page":"13","article-title":"Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia","volume":"88","author":"Passamonti","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2012.07.009_bib49","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/MOH.0b013e32834ff575","article-title":"New generation small-molecule inhibitors in myeloproliferative neoplasms","volume":"19","author":"Passamonti","year":"2012","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.hoc.2012.07.009_bib50","doi-asserted-by":"crossref","first-page":"794240","DOI":"10.1155\/2011\/794240","article-title":"A\u00a0large-scale trial testing the intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera","volume":"2011","author":"Marchioli","year":"2011","journal-title":"Thrombosis"},{"key":"10.1016\/j.hoc.2012.07.009_bib51","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib52","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.hoc.2012.07.009_bib53","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1182\/blood-2012-02-411215","article-title":"A\u00a0polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera","volume":"119","author":"Hernandez-Boluda","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2012.07.009_bib54","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-11-393819","article-title":"Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome","volume":"119","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib55","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib56","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A\u00a0dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib57","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2012.07.009_bib58","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2008-09-178541","article-title":"The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib59","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2141.1988.tb02507.x","article-title":"A\u00a0prognostic classification of myelofibrosis with myeloid metaplasia","volume":"70","author":"Barosi","year":"1988","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2012.07.009_bib60","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1046\/j.1365-2141.1997.1722990.x","article-title":"Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases","volume":"98","author":"Reilly","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2012.07.009_bib61","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1046\/j.1365-2141.1997.782714.x","article-title":"Identification of \u2018short-lived\u2019 and \u2018long-lived\u2019 patients at presentation of idiopathic myelofibrosis","volume":"97","author":"Cervantes","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2012.07.009_bib62","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1046\/j.1365-2141.2001.02796.x","article-title":"Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia","volume":"113","author":"Tefferi","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2012.07.009_bib63","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1182\/blood-2010-06-293415","article-title":"Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis","volume":"116","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib64","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib65","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF01834368","article-title":"Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival","volume":"68","author":"Rupoli","year":"1994","journal-title":"Ann Hematol"},{"key":"10.1016\/j.hoc.2012.07.009_bib66","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/ajh.21391","article-title":"Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis\u2014increased serum ferritin or transfusion load does not","volume":"84","author":"Tefferi","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2012.07.009_bib67","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ajh.21574","article-title":"Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis\u2014prognostic relevance is independent of IPSS or karyotype","volume":"85","author":"Tefferi","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2012.07.009_bib68","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3324\/haematol.2010.031831","article-title":"Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS","volume":"96","author":"Elena","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2012.07.009_bib69","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1182\/blood-2009-12-255943","article-title":"Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients","volume":"115","author":"Morel","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib70","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1600-0609.2009.01373.x","article-title":"Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival","volume":"84","author":"Patnaik","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hoc.2012.07.009_bib71","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1600-0609.1988.tb00191.x","article-title":"Liver involvement at diagnosis of primary myelofibrosis: a clinicopathological study of twenty-two cases","volume":"40","author":"Pereira","year":"1988","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hoc.2012.07.009_bib72","first-page":"272","article-title":"Prognosis of myeloid metaplasia with myelofibrosis","volume":"24","author":"Chelloul","year":"1976","journal-title":"Biomedicine"},{"key":"10.1016\/j.hoc.2012.07.009_bib73","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1182\/blood.V96.10.3374","article-title":"Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia","volume":"96","author":"Mesa","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib74","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1182\/blood.V98.12.3249","article-title":"Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia","volume":"98","author":"Barosi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib75","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2141.2004.05280.x","article-title":"Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients","volume":"128","author":"Arora","year":"2005","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2012.07.009_bib76","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/bmt.2011.17","article-title":"Circulating CD34(+) cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT","volume":"47","author":"Alchalby","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2012.07.009_bib77","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1182\/blood-2009-12-258988","article-title":"Validation of cytogenetic-based risk stratification in primary myelofibrosis","volume":"115","author":"Rumi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib78","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2009-08-240135","article-title":"International prognostic scoring system\u2014independent cytogenetic risk categorization in primary myelofibrosis","volume":"115","author":"Hussein","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib79","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/leu.2010.234","article-title":"Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients","volume":"25","author":"Caramazza","year":"2011","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.hoc.2012.07.009_bib80","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1182\/blood-2010-11-320002","article-title":"Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival","volume":"117","author":"Vaidya","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib81","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib82","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2012.07.009_bib83","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","article-title":"JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis","volume":"110","author":"Barosi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib84","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib85","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2012.07.009_bib86","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2005-08-3395","article-title":"V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis","volume":"107","author":"Campbell","year":"2006","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.hoc.2012.07.009_bib87","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/blood-2009-12-260588","article-title":"Impact of JAK2V617F-mutation status, allele burden and clearance after allogeneic stem cell transplantation for myelofibrosis","volume":"116","author":"Alchalby","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2012.07.009_bib88","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/leu.2009.225","article-title":"JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46\/1 haplotype is associated with inferior survival","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2012.07.009_bib89","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1046\/j.1365-2141.2001.03131.x","article-title":"Comparison of peripheral blood interphase cytogenetics with bone marrow karyotype analysis in myelofibrosis with myeloid metaplasia","volume":"115","author":"Tefferi","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2012.07.009_bib90","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1600-0609.2009.01216.x","article-title":"Karyotype complements the International Prognostic Scoring System for primary myelofibrosis","volume":"82","author":"Hussein","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hoc.2012.07.009_bib91","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1600-0609.2009.01298.x","article-title":"The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan","volume":"83","author":"Hidaka","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hoc.2012.07.009_bib92","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.leukres.2010.07.015","article-title":"What are RBC-transfusion-dependence and -independence?","volume":"35","author":"Gale","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.hoc.2012.07.009_bib93","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2012.07.009_bib94","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2012.07.009_bib95","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2012.07.009_bib96","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1200\/JCO.2011.39.0310","article-title":"Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms","volume":"30","author":"Pardanani","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2012.07.009_bib97","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/blood-2011-08-372904","article-title":"The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation","volume":"119","author":"Scott","year":"2012","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858812001335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858812001335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:56:55Z","timestamp":1760183815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858812001335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":97,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0889858812001335"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2012.07.009","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Predictors of Outcome in MPN","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2012.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}